Tiansli Pre-IPO round has the highest valuation, being the largest unicorn in the domestic biopharmaceon field

While biotech innovation has pushed China into a new era of biomedicine, it has spawned a large number of innovative enterprises dubbed "unicorns". With the recent introduction of the Hong Kong Stock Exchange to allow domestic biopharmace companies to list in Hong Kong, biopharmaceon companies frequently out of the financing information, who is the largest biopharmaceon listed in Hong Kong this year, "
unicorn"? Recently, Tiansli Biopharmaceutical Co., Ltd. ("Tiansli Bio"), an innovative biopharmaceutical company with a listed heavy-weight product in the cardiovascular sector and the industry's ability to develop pipelines, announced the completion of the Pre-IPO round of financing, with a post-investment valuation of 12.5 billion yuan ($1.9 billion). The financing was led by Hong Kong Huiqiao Capital, followed by France's Merrier Group and well-known Chinese institutions, with a financing quota of about 1 billion yuan (nearly $150 million). This not only means that the financing has become the largest financing in the field of innovative pharmaceuticals in China, making Tiansli Bio the highest valuation biopharmaceutical company listed in Hong Kong, but also marks a solid step towards the goal of becoming a leader in biopharmaceuticals in the Hong Kong capital market.
Pre-IPO round was valued at nearly $2 billion, exceeding industry expectations
Public data show that the valuation of biopharmaceus companies represented by Xinda Bio, Fuhong Hanxuan, etc. is about $1.5 billion; Biopharmaceity companies represented by Goli Bio and Huali Pharmaceuticals are valued at US$1 billion; Companies represented by Tiantian Bio, Lizhu Mono-Resistance, etc. are valued at between $500 million and $1 billion. By contrast, only Tiansli Bio has surpassed the $1.5 billion industry's height and is close to a $2 billion valuation, leading the way in listing biopharmaceutical companies in Hong Kong.
the results, several industry agencies commented: "Beyond expectations but reasonable." Reporters found that Guangfa Securities, Guotai Junan Securities, CITIC Securities, Oriental Securities, a number of institutions have previously issued in-depth reports: Tiansli Pharmaceutical adhere to the strategy of coordinated development of Traditional Chinese medicine, chemical drugs, biological drugs, Tiansli Bio is the core platform of its biopharmaceutical strategy, this part of the assets have not received effective attention from the market. That is to say, Tianshili Pharmaceuticals, as the parent company of Tianshili Bio, has only been given a lower valuation of traditional Chinese medicine by the industry, and has not received a fair evaluation from the market.
fact, compared with most biotech companies in the industry with a history of 3-5 years, Tiansli Bio has a 17-year history as a wholly owned subsidiary of Tiansli Pharmaceutical Group. The company began using biotechnology in 2001 for the development of the cardiovascular and cerebrovascular therapy drug, "Puyuk", which was officially launched in 2011 as the only new drug approved during the 11th Five-Year Plan period. Puyuk from research and development to the market to promote the implementation of tiansli Chinese medicine, chemical drugs, biological drugs coordinated development strategy, but also let China's long-term can not get timely and effective treatment of cardiovascular disease patients benefit.heavy product expectations and unique platform model recognized Many institutional investors believe that with the rapid entry of multinational biopharmaceuticals into the Chinese market, leaving The time window dividend for Chinese pharmaceutical companies to narrow, how to deeply occupy the market and have platform combat capabilities, so as to ensure that the continuous breakthrough in research products has become a major issue for Chinese biopharmaceutical enterprises.
institutions believe that Puyuk as the future 8 billion yuan super sales varieties can become the ace of Tiansli biological expansion of the Chinese market, while the research, production, marketing, investment integration of mature commercial platform has been market tested, can resist the upcoming chinese biopharmaceity market competition risks, so the highest valuation in the industry is based on the future market trends of rational judgment.
data show that, with the simple outstanding research and development capabilities, there is no product listing of other pharmaceutical companies to form a huge difference, Tiansli biofocus cardiovascular, tumor immunity, digestive metabolism three major markets and high-growth treatment areas, currently become the only listed companies in Hong Kong with listed products, while establishing a set of research and development, production, sales integration of the scarce whole industrial chain commercial platform.
Puyuk, a highly-profile heavy-weight biopharmaceutical product, was included in the National Health Insurance Directory in 2017 and is a world leader in specific thrombosis and is expected to become the market's number one brand for the treatment of acute ST-stage elevated myocardial infarction (STEMI).
, the company has also shown strong strength in independent research and development and in cooperation with the world's leading pharmaceutical companies. Currently in the research pipeline more than 15 varieties. One of the most representative is for more than 3 million patients of Puyuk stroke adaptation research and development, has entered Phase III clinical trials; Amgen monoantigen, which is used to treat colorectal cancer in more than 400,000 patients, is about to enter Phase II clinical trials; The T101 vaccine for nearly 100 million patients for the treatment of hepatitis B is currently in Phase I clinical trials. In addition, Tiansli bio-strategic layout of the third generation of insulin products, by virtue of surpassing the world's three major manufacturers of diabetes products, is currently actively declared the European Union, a large group of Chinese diabetics will soon benefit from world-class quality Chinese insulin products.
Solid capital reserves, strong resource endorsements from parent companies and the support of many well-known institutions will make Tiansli Bio more active in the future to promote innovative research and development and market strategy, help Tiansli Bio further promote innovative product pipeline, strengthen its leading position in the field of cardiovascular and cerebrovascular, while promoting the progress of research and development in tumor immunity, digestion and metabolism, and ultimately bring Affordable World Quality Biopharmaceous drugs to Chinese patients. (Tiansli Enterprises Website)